case_images: PMC6352649_01
case_images: Positron emission tomography/computed tomography image of the fibrous (benign) pulmonary meningioma
case_images: IJNM-34-45-g001.jpg
case_images: PMC6352649_01_IJNM-34-45-g001.jpg
case_images: F1
case_images: PET/CT images showed a metabolically active lesion (SUVmax 4.63 g/ml bw, 14 mm in diameter), suspected of being a metastasis [Figure 1].
case_images: Contrast-enhanced computed tomography image of the fibrous (benign) pulmonary meningioma
case_images: IJNM-34-45-g002.jpg
case_images: PMC6352649_01_IJNM-34-45-g002.jpg
case_images: F2
case_images: Contrast-enhanced CT with iodinated contrast media performed after PET examination did not show significant attenuation between pre- and postcontrast phase [Figure 2].
case_images: Positron emission tomography/computed tomography image of the malignant pulmonary meningioma
case_images: IJNM-34-45-g003.jpg
case_images: PMC6352649_01_IJNM-34-45-g003.jpg
case_images: F3
case_images: In June 2016, another 18F FDG PET/CT scan was performed in the same patient (injected dose 361 MBq) that showed another new metabolically active pseudonodular lesion (SUVmax 2.46 g/ml bw, 12 mm in diameter) in the superior lobe of the left lung [Figure 3].
case_images: Contrast-enhanced computed tomography image of malignant pulmonary meningioma
case_images: IJNM-34-45-g004.jpg
case_images: PMC6352649_01_IJNM-34-45-g004.jpg
case_images: F4
case_images: A CT scan with iodinated contrast, the lesion showed enhancement at postcontrast phase [basal scan:-1 HU; postcontrast scan: 55 HU, Figure 4].